Pancreatic cancer is expected to become the second leading cause of the cancer related deaths in the USA by 2020. The goal of all pre-clinical magnetic resonance imaging (MRI) studies is to translate the pre-clinical MR values to the clinical scanners and ultimately to human population. MRI has been proven to be extremely useful in clinical trials for monitoring tumor development and assessing therapeutic effects of novel therapeutic strategies. The aim of this study was to measure (T2) relaxation time and magnetization ratio (MTR) in a mouse model of pancreatic ductal adenocarcinoma (PDA) at pre-clinical (14T) and clinical (3T) scanner.
This abstract and the presentation materials are available to members only; a login is required.